CreativeOne Wealth LLC Has $3.81 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

CreativeOne Wealth LLC lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 28.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 41,240 shares of the biopharmaceutical company's stock after buying an additional 9,105 shares during the period. CreativeOne Wealth LLC's holdings in Gilead Sciences were worth $3,809,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Westside Investment Management Inc. increased its holdings in shares of Gilead Sciences by 3.5% during the third quarter. Westside Investment Management Inc. now owns 27,443 shares of the biopharmaceutical company's stock valued at $2,249,000 after purchasing an additional 917 shares during the period. SkyView Investment Advisors LLC increased its stake in Gilead Sciences by 5.4% during the 3rd quarter. SkyView Investment Advisors LLC now owns 8,482 shares of the biopharmaceutical company's stock valued at $711,000 after buying an additional 435 shares during the period. Pine Valley Investments Ltd Liability Co bought a new stake in shares of Gilead Sciences during the 3rd quarter worth about $209,000. World Investment Advisors LLC lifted its stake in shares of Gilead Sciences by 33.6% in the 3rd quarter. World Investment Advisors LLC now owns 25,999 shares of the biopharmaceutical company's stock worth $2,180,000 after acquiring an additional 6,535 shares during the period. Finally, Arvest Bank Trust Division bought a new position in shares of Gilead Sciences in the third quarter valued at approximately $9,661,000. 83.67% of the stock is owned by institutional investors.

Remove Ads

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 137,676 shares of the business's stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $102.22, for a total transaction of $14,073,240.72. Following the completion of the transaction, the chief financial officer now owns 171,223 shares of the company's stock, valued at approximately $17,502,415.06. The trade was a 44.57 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 302,785 shares of company stock worth $30,540,875 over the last ninety days. Company insiders own 0.16% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on GILD shares. Wells Fargo & Company increased their price target on Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Oppenheimer raised their price objective on Gilead Sciences from $115.00 to $132.00 and gave the stock an "outperform" rating in a research note on Tuesday, March 4th. The Goldman Sachs Group boosted their target price on Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 12th. Morgan Stanley lifted their price target on Gilead Sciences from $123.00 to $130.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 11th. Finally, Piper Sandler upped their price objective on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a research note on Wednesday, February 12th. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $105.12.

Gilead Sciences Stock Down 0.8 %

Gilead Sciences stock traded down $0.80 during mid-day trading on Wednesday, hitting $104.88. 7,115,838 shares of the company's stock were exchanged, compared to its average volume of 7,504,431. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96. The stock has a 50 day moving average of $108.63 and a two-hundred day moving average of $97.11. The stock has a market cap of $130.59 billion, a P/E ratio of 283.46, a P/E/G ratio of 0.71 and a beta of 0.32. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were given a dividend of $0.79 per share. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.77. The ex-dividend date of this dividend was Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a yield of 3.01%. Gilead Sciences's payout ratio is currently 854.05%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.